3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Terminated
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
7
Retroperitoneal liposarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Melanoma
1
Liposarcoma
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Acute
1
Leiomyosarcoma
1
Chondrosarcoma
1
Interventions
Cytarabine
55
Decitabine
33
Azacitidine
30
Idarubicin
22
venetoclax
21
fludarabine
16
Cyclophosphamide
16
Granulocyte Colony-Stimulating Factor
15
Daunorubicin
12
Mitoxantrone
9
Etoposide
8
Cladribine
8
Busulfan
8
Aclarubicin
8
Homoharringtonine
7
Filgrastim
7
Peripheral Blood Stem Cell Transplantation
6
fludarabine phosphate
5
aclacinomycins
4
Tretinoin
4
Sorafenib
4
Radiotherapy
4
Polymerase Chain Reaction
4
Mycophenolic Acid
4
Lenalidomide
4
Gemtuzumab
4
Cyclosporine
4
Clofarabine
4
Arsenic Trioxide
4
sargramostim
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Leukemia, Myeloid, Acute
×
nilotinib
×
Clear all
NCT01690065
2016-05-11
NICE-BORA
Ulsan University Hospital
Phase 2
Unknown
46 enrolled